Anavex Life Sciences Corp (fra:12X1) Share Price

Company Profile

Business description
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.
Contact
630 5th Avenue
20th Floor
New YorkNY10111
USA
T: +1 844 689-3939
E: [email protected]
https://www.anavex.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 September 2026
Employees
2

Recommended

We think Microsoft stock is moderately undervalued.

Dan Romanoff, CPA | 30 October 2025

Q3 earnings reflected sequential improvement driven by record auto deliveries and energy storage deployments.

Seth Goldstein, CFA | 30 October 2025

Well priced Aussie shares that offer a tax rebate.

Shani Jayamanne | 29 October 2025

Index	Last price	Change	% Change
All Ordinaries	9,178.00	28.70	-0.31%
CAC 40	8,121.07	79.81	-0.97%
DAX 40	23,958.30	160.59	-0.67%
Dow JONES (US)	47,562.87	40.75	0.09%
FTSE 100	9,717.25	42.81	-0.44%
HKSE	25,906.65	376.04	-1.43%
NASDAQ	23,724.96	143.81	0.61%
Nikkei 225	52,411.34	1,085.73	2.12%
NZX 50 Index	13,548.32	89.03	0.66%
S&P 500	6,840.20	17.86	0.26%
S&P/ASX 200	8,881.90	31.30	-0.35%
SSE Composite Index	3,954.79	32.11	-0.81%